IDEAS home Printed from
   My bibliography  Save this article

Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness


  • Manuel Neves

    (Clinical Center of the Champalimaud Center for the Unknown)

  • Fernanda Trigo

    (Centro Hospitalar S. João)

  • Bergantim Rui

    (Centro Hospitalar S. João)

  • Cristina João

    (Clinical Center of the Champalimaud Center for the Unknown)

  • Paulo Lúcio

    (Clinical Center of the Champalimaud Center for the Unknown)

  • Neves Mariana

    (IQVIA Solutions Portugal)

  • João Mendes

    (Janssen Portugal)

  • Hugo Pedrosa

    (IQVIA Solutions Portugal
    Lagoas Park)

  • Catarina Geraldes

    (Centro Hospitalar e Universitário de Coimbra)


Background Multiple myeloma (MM) is the second most common hematological cancer worldwide and has significant morbidity and mortality and is increasing in incidence. While MM management costs are considerable, specific economic data at the country level remain scarce. Objective This study assesses the burden and cost of MM in Portugal from the perspective of the National Health Service (NHS) to support the definition of health policies, resource allocation and patient care. Methods Developed by the Portuguese Multiple Myeloma Group, this study considers the most recent available data. Burden of disease was measured using disability-adjusted life-years (DALYs). The cost of MM was estimated using a prevalence-based model that estimated direct costs for the NHS considering all costs associated with diagnosis, hospitalizations, surgeries, emergency visits, medical appointments, drugs and transportation. Costs were quantified based on the diagnosis-related group funding price, except for drug usage, which was calculated using the average hospital product stock price. Results The burden of disease attributable to MM for 2018 was estimated at 8931 DALYs: 8570 resulting from premature deaths and 361 from disability. Average yearly direct costs per patients with MM amounted to €31,449 (year 2018 values). Total direct costs are estimated at €61 million per year. Conclusions The mortality rate in MM means that most DALYs are due to years of life lost rather than years lost due to disability. This study generates comprehensive data on the burden and cost of MM in Portugal and provides updated insights into the costs associated with the management of MM.

Suggested Citation

  • Manuel Neves & Fernanda Trigo & Bergantim Rui & Cristina João & Paulo Lúcio & Neves Mariana & João Mendes & Hugo Pedrosa & Catarina Geraldes, 2021. "Multiple Myeloma in Portugal: Burden of Disease and Cost of Illness," PharmacoEconomics, Springer, vol. 39(5), pages 579-587, May.
  • Handle: RePEc:spr:pharme:v:39:y:2021:i:5:d:10.1007_s40273-020-00993-5
    DOI: 10.1007/s40273-020-00993-5

    Download full text from publisher

    File URL:
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL:
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item

    As the access to this document is restricted, you may want to search for a different version of it.


    Blog mentions

    As found by, the blog aggregator for Economics research:
    1. Journal round-up: PharmacoEconomics 39(5)
      by Don Husereau in The Academic Health Economists' Blog on 2021-07-16 06:00:06


    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.

    Cited by:

    1. Jacopo Garlasco & Mario Cesare Nurchis & Valerio Bordino & Martina Sapienza & Gerardo Altamura & Gianfranco Damiani & Maria Michela Gianino, 2022. "Cancers: What Are the Costs in Relation to Disability-Adjusted Life Years? A Systematic Review and Meta-Analysis," IJERPH, MDPI, vol. 19(8), pages 1-17, April.
    2. Zeki Kocaata & Thomas Wilke & Franz Fischer & Robert Welte & Hermann Einsele, 2022. "Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis," PharmacoEconomics - Open, Springer, vol. 6(4), pages 619-628, July.
    3. Antoine Bessou & Xavier Colin & Julie De Nascimento & Will Sopwith & Shannon Ferrante & Boris Gorsh & Benjamin Gutierrez & Leah Sansbury & Jenny Willson & Sandhya Sapra & Prani Paka & Feng Wang, 2023. "Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective co," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 321-333, April.

    More about this item


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:39:y:2021:i:5:d:10.1007_s40273-020-00993-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.